Ken Fisher’s Dividend Stock Picks

Ken Fisher, the founder of Fisher Asset Management, is a Forbes portfolio strategy columnist, a New York Times best-selling author, and an investment guru. In early February, Fisher and the Investment Policy Committee of his firm released their forecast for the stock market and global macro-economy for the year ahead. According to Fisher, the growing corporate revenues and profits and attractive stock valuations are likely to continue in 2012. Global economy is also likely to continue reaching new highs in the year ahead. Fisher seems to be optimistic about the market. We agree with him. We think dividend stocks will outperform bonds in the next couple of years. In this article, we are going to take a closer look at a few dividend stock picks of Fisher. All companies have at least 3% dividend yield.

Ken Fisher - FISHER ASSET MANAGEMENT

Company Dividend Yield Value (*1000)
Johnson & Johnson (JNJ) 3.54% 668403
Abbott Laboratories (ABT) 3.62% 523293
GlaxoSmithKline plc (GSK) 5.11% 515817
Pfizer Inc (PFE) 4.14% 471268
Intel Corporation (INTC) 3.16% 463461
Sanofi (SNY) 4.75% 432370

Johnson & Johnson (JNJ) is the largest dividend position in Fisher’s latest 13F portfolio. At the end of last year, Fisher had $668 million invested in this position. The stock was also quite popular among hedge funds. At the end of last year, there were 59 hedge funds with JNJ positions in their 13F portfolios. Billionaire Warren Buffett’s Berkshire Hathaway had about $2 billion invested in JNJ (see Warren Buffett’s new stock picks).

We like JNJ too. It has a decent dividend yield of 3.54%, versus 2% for 10-year Treasury bonds. The company also has an impressive record of increasing its dividend payouts. It has been raising its dividend for 49 consecutive years. We think JNJ will continue elevating its dividends in the future. Its current payout ratio is 64% and its earnings are expected to grow at about 6% per year. The company’s stable businesses with low exposure to market risk also indicate that it has the ability to maintain or even increase its dividend payments. JNJ’s products are almost independent of economic cycles. Its diversified portfolio of products, including medical devices, drugs, and consumer products, also largely reduces the overall risk it is exposed to. JNJ also looks attractive when it comes to valuation. Its forward P/E ratio is 11.85, versus 16.04 for the average of pharmaceutical stocks. We think JNJ is an attractive dividend growth stock for long-term investors.

One of the major competitors of JNJ is Abbott Laboratories (ABT). Fisher is bullish about ABT as well. At the end of last year, Fisher had $523 million invested in ABT. ABT was also quite popular among hedge funds tracked by us. At the end of the third quarter last year, there were 37 hedge funds reported to own ABT in their 13F portfolios. For instance, Ric Dillon’s Diamond Hill Capital and Bill Miller’s Legg Mason Capital Management both had over $100 million invested in this stock. Jim Simons’ Renaissance Technologies also had $11 million invested in ABT at the end of last year. Similar to JNJ, ABT also has a decent dividend yield of 3.62% and it has been raising its dividend payouts for 39 consecutive years. We are also optimistic about the company’s dividend growth in the future. ABT’s current payout ratio is 62% and its earnings are expected to grow at 7.51% annually. ABT’s forward P/E ratio of 10.55 is also lower than the 16.04 for industry average. Moreover, the company is planning to split up itself by spinning off its research-based pharmaceutical business. The spinoff is expected to be completed at the end of this year. We think the planned spin-off will lead to higher valuations for each company and investors will be benefit from that.

Most of Fisher’s dividend stock picks are in the pharmaceuticals industry. GlaxoSmithKline Plc (GSK), Sanofi (SNY), Pfizer Inc (PFE), and Intel Corporation (INTC) are among his other large bets. Pfizer and Sanofi are the two most popular healthcare stocks among hedge funds (see the 10 most popular stocks). We think the market undervalues this industry because of concerns about patent expirations. They are trading at historically low price multiples and we actually expect healthcare spending grow more than expected as Obama’s health reform kicks in. SNY and PFE have forward P/E ratios of below 9. Their expected growth rates are also very low so they are great options for contrarian investors.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!